Business Context and Reporting Period
SciSparc Ltd., a foreign private issuer headquartered in Tel Aviv, Israel, filed Form 6-K on August 12, 2026. The report covers the month of August 2026 and primarily discloses a corporate development regarding its subsidiary, NeuroThera Labs.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a specific event rather than a financial statement.
Material Changes
The material change disclosed is the granting of a Japanese patent to SciSparc's subsidiary, NeuroThera Labs, for its proprietary, innovative therapeutic combination. No financial performance changes were reported in this document.
Guidance, Outlook, and Risks
The filing incorporates a press release detailing the patent grant but does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the general incorporation by reference into existing registration statements.
Investor Verification Checklist
- Verify the scope and commercial potential of the Japanese patent granted to NeuroThera Labs.
- Review the full text of the press release (Exhibit 99.1) for details on the therapeutic combination.
- Check subsequent filings for any financial impact or regulatory milestones related to this patent.